PALATINE, Ill., and BRISTOL, Tenn., March 3, 2009 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) (the Companies) today announced that Acura's New Drug Application (NDA) for Acurox(r) (oxycodone HCl/niacin) Tablets was accepted for filing by the U.S. Food and Drug Administration (FDA) with a Priority review classification. Acurox(r) is an immediate release opioid analgesic, has a proposed indication for relief of moderate-to-severe pain and is designed to deter common methods of misuse and abuse.
